Integrated Approaches for Liver Fibrosis Treatment are anticipated to open up new avenue for Liver Fibrosis Treatment Market

Liver Fibrosis Treatment Market

Market Overview:

Liver fibrosis is characterized by excessive accumulation of extracellular matrix proteins in the liver which disrupts the normal liver architecture and function. Key causes of liver fibrosis include chronic hepatitis B and C virus infections, excessive alcohol consumption and non-alcoholic steatohepatitis (NASH). The current treatment landscape includes antiviral drugs, corticosteroids and immunosuppressive agents. However, there is an urgent need for effective anti-fibrotic therapies to halt or reverse the fibrosis process.

Market Dynamics:

Two key drivers of the liver fibrosis treatment market are growing prevalence of chronic liver diseases and large therapeutic opportunity. Chronic hepatitis B and C affect nearly 300 million people globally and are leading risk factors for liver fibrosis. In addition, the global burden of NASH is rising rapidly due to the obesity and diabetes pandemic. Effective anti-fibrotic drugs can halt disease progression and reduce the need for costly late-stage treatments like liver transplantation. Several candidates are in the pipeline targeting key molecular pathways involved in fibrosis development. For example, galectin-3 inhibitors reduce fibrogenesis by blocking galectin-3 mediated collagen deposition. Successful approvals will drive significant market growth in the forecast period.

The global Liver Fibrosis Treatment Market Size is estimated to be valued at US$ 16.29 Bn in 2023 and is expected to exhibit a CAGR of 10.8 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Segment Analysis

The global liver fibrosis treatment market is segmented into Imaging techniques, anti-fibrotic drugs, immunomodulators, liver transplantation and others. The anti-fibrotic drugs segment dominates the market and accounts for the largest revenue share. This is mainly because anti-fibrotic drugs such as monoclonal antibodies, proteasome inhibitors and interferons are highly prescribed by physicians as first line therapies to treat liver fibrosis.

PEST Analysis

Political: The government across various countries are steadily increasing healthcare expenditure to curb the growing burden of liver diseases. This is positively impacting the growth of the liver fibrosis treatment market.

Economic: The rising per capita income levels have increased healthcare spending capacity among individuals globally. This provides a conducive environment for market growth.

Social: Growing awareness about lifestyle-related liver disorders and available treatment options through various health programs is driving more patients to seek diagnosis and treatment.

Technological: Advancements in imaging technologies help detect fibrosis at an early stage. Development of novel anti-fibrotic drugs with higher efficacy and improved tolerability is further fueling the market expansion.

Key Takeaways

The global liver fibrosis treatment market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of chronic liver diseases such as hepatitis, non-alcoholic fatty liver disease and others. The market size for 2023 is estimated at US$ 16.29 Bn.

Regional analysis shows that North America commands the largest share in the global market owing to growing obesity rates and availability of advanced treatment options. Europe also captures a significant share and is projecting lucrative growth prospects supported by rising alcoholic liver disease incidence and strong healthcare infrastructure.

Key players operating in the liver fibrosis treatment market are Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited. These companies are focusing on developing novel treatment approaches through extensive R&D initiatives and clinical trials to gain higher market share.

For more details on the report,  Read-

https://www.pressreleasebulletin.com/liver-fibrosis-treatment-market-size-and-share/